Abbott introduces single-dose formulation of carbetocin in India

Drug major Abbott on Tuesday said it has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum haemorrhage (PPH)

Abbott
Press Trust of India New Delhi
2 min read Last Updated : Aug 31 2021 | 3:24 PM IST

Drug major Abbott on Tuesday said it has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum haemorrhage (PPH).

PPH refers to excessive blood loss of 500 ml or more after vaginal delivery and 1,000 ml or more after a caesarean procedure, within 24 hours of childbirth.

Although preventable, PPH is associated with almost 20 per cent maternal mortality in the country.

PPH, if left untreated, can result in complications like anaemia in the postpartum period or aggravate mental health problems including postnatal depression and post-traumatic stress disorder apart from other issues.

The current prevention and treatment protocol for PPH requires cold-chain storage and distribution, as well as continual administration of medicines via intravenous drip infusion, Abbott said in a statement.

This can impede access to quality healthcare for pregnant women in care settings where these requirements may not be feasible, it added.

"The room-temperature-stable formulation addresses the challenge of maintaining cold-chain storage or transportation, which helps increase access to preventive treatment for PPH, across geographies," it added.

Abbott has launched this formulation for the private market under its own brand through an in-licensing and co-marketing agreement with Ferring Pharmaceuticals Pvt Ltd India (Ferring), a subsidiary of the Switzerland-based global biopharmaceuticals company.

With the introduction of this room-temperature- stable carbetocin formulation in collaboration with Ferring, we are reiterating our commitment to improve maternal care, enabling both mothers and children to live through better health.

"This formulation has proven efficacy, a convenient formulation that addresses the needs for heat stability and can help with better health outcomes for mothers who just delivered a baby," Abbott India Medical Director Srirupa Das said.

Abbott initiated operations in India in 1910 and has over 12,000 employees in the country.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Abbott IndiaAbbott LaboratoriesPharma industry

First Published: Aug 31 2021 | 3:24 PM IST

Next Story